TY - JOUR
T1 - Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3Dechocardiography and 3Dstrain in heart failure with reduced ejection fraction patients
AU - Öz, Tugba K.
AU - Abdelnabi, Mahmoud
AU - Fiore, Corrado
AU - Almaghraby, Abdallah
AU - Cihan, Deniz
AU - Babazade, Nigar
AU - Naqvi, Syed Haseeb Raza
AU - Omar, Bahadir
AU - Dagdeviren, Bahadir
N1 - Publisher Copyright:
© 2022 Journal of Korean Ophthalmological Society. All rights reserved.
PY - 2022/8
Y1 - 2022/8
N2 - BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3Dechocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3Dstrain parameters. METHODS: Asingle-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters. RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65±4.98% to 32.89±6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/ valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up. CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.
AB - BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3Dechocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3Dstrain parameters. METHODS: Asingle-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters. RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65±4.98% to 32.89±6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/ valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up. CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.
KW - Echocardiography, three-dimensional
KW - Heart Failure, systolic
KW - Sacubitril
KW - Valsartan
KW - Ventricular remodeling
UR - http://www.scopus.com/inward/record.url?scp=85135419373&partnerID=8YFLogxK
U2 - 10.23736/S2724-5683.21.05802-6
DO - 10.23736/S2724-5683.21.05802-6
M3 - Article
C2 - 34713680
AN - SCOPUS:85135419373
SN - 2724-5683
VL - 70
SP - 431
EP - 438
JO - Minerva Cardiology and Angiology
JF - Minerva Cardiology and Angiology
IS - 4
ER -